CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
P/E ratio for CytoMed Therapeutics Limited (GDTC)
P/E ratio as of 2023: -21.94
According to CytoMed Therapeutics Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.94. At the end of 2022 the company had a P/E ratio of -13.15.
P/E ratio history for CytoMed Therapeutics Limited from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -21.94 |
| 2022 | -13.15 |
| 2021 | -18.03 |
| 2020 | -16.05 |
| 2019 | -47.25 |